{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:00:07Z","timestamp":1782990007783,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00280-021-04356-5","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T18:11:24Z","timestamp":1632939084000},"page":"267-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6940-333X","authenticated-orcid":false,"given":"Annalisa","family":"Condorelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Leotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Schinin\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Sciortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna Maria","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziatina Laura","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Proietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Camuglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"issue":"3","key":"4356_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D et al (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4(3):362\u2013375. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0609","journal-title":"Cancer Discov"},{"issue":"4","key":"4356_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1513257","journal-title":"N Engl J Med"},{"issue":"10","key":"4356_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J et al (2016) Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6(10):1106\u20131117. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313","journal-title":"Cancer Discov"},{"issue":"Supplement 1","key":"4356_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1182\/blood-2018-99-118729","volume":"132","author":"A Wei","year":"2018","unstructured":"Wei A, Strickland SA, Hou J-Z et al (2018) Venetoclax with low-dose cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy. Blood 132(Supplement 1):284\u2013284. https:\/\/doi.org\/10.1182\/blood-2018-99-118729","journal-title":"Blood"},{"issue":"2","key":"4356_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216\u2013228. https:\/\/doi.org\/10.1016\/S1470-2045(18)30010-X","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"4356_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2018-99-113670","volume":"132","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Pillai R et al (2018) Response to venetoclax and hypomethylating agents among prognostic risk groups and genetic subtypes of acute myeloid leukemia. Blood 132(Supplement 1):334\u2013334. https:\/\/doi.org\/10.1182\/blood-2018-99-113670","journal-title":"Blood"},{"issue":"9","key":"4356_CR7","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A et al (2018) Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103(9):e404\u2013e407. https:\/\/doi.org\/10.3324\/haematol.2018.188094","journal-title":"Haematologica"},{"issue":"3","key":"4356_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Rausch CR, Benton C et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401\u2013407. https:\/\/doi.org\/10.1002\/ajh.25000","journal-title":"Am J Hematol"},{"issue":"5","key":"4356_CR9","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3324\/haematol.2018.213157","volume":"104","author":"G Reda","year":"2019","unstructured":"Reda G, Cassin R, Dovrtelova G et al (2019) Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica 104(5):e222\u2013e223. https:\/\/doi.org\/10.3324\/haematol.2018.213157","journal-title":"Haematologica"},{"issue":"3","key":"4356_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-016-0485-9","volume":"37","author":"AH Salem","year":"2017","unstructured":"Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL (2017) Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers. Clin Drug Investig 37(3):303\u2013309. https:\/\/doi.org\/10.1007\/s40261-016-0485-9","journal-title":"Clin Drug Investig"},{"issue":"11","key":"4356_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, Van Der Mech\u00e9 FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve 14(11):1103\u20131109. https:\/\/doi.org\/10.1002\/mus.880141111","journal-title":"Muscle Nerve"},{"issue":"1","key":"4356_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.xphs.2017.09.027","volume":"107","author":"A Emami Riedmaier","year":"2018","unstructured":"Emami Riedmaier A, Lindley DJ, Hall JA et al (2018) Mechanistic physiologically based pharmacokinetic modeling of the dissolution and food effect of a biopharmaceutics Classification System IV Compound\u2014the venetoclax story. J Pharm Sci 107(1):495\u2013502. https:\/\/doi.org\/10.1016\/j.xphs.2017.09.027","journal-title":"J Pharm Sci"},{"issue":"5","key":"4356_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s12185-016-2063-6","volume":"104","author":"JH Kwon","year":"2016","unstructured":"Kwon JH, Koh Y, Yoon SS, Park S, Kim I (2016) Clinical outcome and efficacy of current anti-leukemic therapy for leptomeningeal involvement in acute myeloid leukemia. Int J Hematol 104(5):574\u2013581. https:\/\/doi.org\/10.1007\/s12185-016-2063-6","journal-title":"Int J Hematol"},{"issue":"4","key":"4356_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2018.02.006","volume":"55","author":"MI Del Principe","year":"2018","unstructured":"Del Principe MI, Buccisano F, Soddu S et al (2018) Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. Semin Hematol 55(4):209\u2013214","journal-title":"Semin Hematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04356-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T17:39:42Z","timestamp":1643737182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04356-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4356"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04356-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}